Wolverine Asset Management’s LumiraDx Limited Warrant LMDXW Stock Holding History

Wolverine Asset Management’s Portfolio LMDXW Stock Details LMDXW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-28,630	Closed	-$246	–	2005
2023 Q4	$246	Buy	28,630 +2,400	+9%	+$36	﹤0.01%	1692
2023 Q3	$760	Buy	26,230 +805	+3%	+$30	﹤0.01%	1721
2023 Q2	$760	Buy	25,425 +1,550	+6%	+$85	﹤0.01%	1661
2023 Q1	$2.8K	Buy	23,875 +1,433	+6%	+$121	﹤0.01%	1612
2022 Q4	$1.32K	Buy	22,442 +7,323	+48%	+$1K	﹤0.01%	1918
2022 Q3	$1K	Buy	+15,119	New	+$5.03K	﹤0.01%	2340
2021 Q4	–	Sell	-5,000	Closed	-$5K	–	2285
2021 Q3	$5K	Buy	+5,000	New	+$5.8K	﹤0.01%	1858

Other funds holding LMDXW

CVS Health Woonsocket, Rhode Island $212M AUM 19.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Wolverine Asset Management's LMDXW Position: Q1 2024 in Review

Wolverine Asset Management sold out of LumiraDx Limited Warrant (LMDXW) in Q1 2024, closing a stake of 28,630 shares — an estimated $246 sold.

Wolverine Asset Management first reported a position in LMDXW in Q3 2021 and held it in 7 quarters. The position peaked at $5K in Q3 2021. 4 funds tracked by Wall St. Rank hold LMDXW as of Q1 2024.

Wolverine Asset Management reported no remaining LumiraDx Limited Warrant position as of Q1 2024 after selling out during the quarter.
Wolverine Asset Management sold 28,630 LumiraDx Limited Warrant shares in Q1 2024, an estimated $246.
Wolverine Asset Management first reported a position in LumiraDx Limited Warrant in Q3 2021 and held it in 7 quarters.
Wolverine Asset Management's LumiraDx Limited Warrant position peaked at $5K in Q3 2021.
4 funds tracked by Wall St. Rank held LumiraDx Limited Warrant as of Q1 2024.

Based on Wolverine Asset Management's 13F filing for Q1 2024, filed 13 May 2024.